An observational study in Hepatitis B, sponsored by GlaxoSmithKline. Completed. Per ClinicalTrials.gov, last updated 2013-05-29.
Sponsored by GlaxoSmithKline · Observational
This post-marketing surveillance (PMS) is conducted to collect safety and efficacy data among subjects with chronic hepatitis B and hepatic cirrhosis B who is treated with adefovir tablets.
1,656 studies on the registry are indexed under Hepatitis B; 196 are open to participants now.
This study's enrollment of 436 is above the median of 390 across 407 observational studies indexed under Hepatitis B.
Browse Hepatitis B studies →GlaxoSmithKline is the lead sponsor of 3,562 studies on the registry; 117 are open to participants now.
Of its 258 completed or terminated interventional studies of FDA-regulated products, 232 (90%) have results posted.
Counted across the registry records on this site, refreshed daily.
Subjects with chronic hepatitis B or hepatic cirrhosis B who are confirmed of hepatic function abnormality with continuous re-proliferation of hepatitis B virus while treated with lamivudine
Exclusion Criteria:
Subjects with chronic hepatitis B or hepatic cirrhosis B to whom adefovir tablets are administered
Drug: Adefovir tablets
Administered according to the prescribing information in the locally approved label by the authorities.
The incidence of adverse drug reactions
Time frame: 1 year
No study locations are listed for this record.
This study is completed, as verified in May 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
GlaxoSmithKline